Ramiro Guerrero, a director at MAIA Biotechnology, Inc. (AMEX:MAIA), recently acquired a significant amount of company stock, as detailed in a recent SEC filing. Guerrero purchased 53,418 shares of common stock at a price of approximately $1.872 per share. The purchase comes as the stock has shown remarkable strength, delivering a 139% return over the past year. According to InvestingPro analysis, the stock is currently trading near its Fair Value. This transaction, completed on December 13, 2024, amounts to a total investment of $99,998.
The shares were acquired under a Securities Purchase Agreement and issued as part of MAIA's 2021 Equity Incentive Plan. Following this transaction, Guerrero now holds a total of 514,970 shares of MAIA Biotechnology. This move reflects a continued commitment to the company, as Guerrero also holds warrants for an additional 53,418 shares, exercisable at $2.08 per share, starting June 2025.
In other recent news, MAIA Biotechnology, Inc. has expanded its ongoing Phase 2 clinical trial, THIO-101, to further evaluate the efficacy of its lead drug candidate THIO in combination with Regeneron (NASDAQ:REGN)'s Libtayo® for the treatment of third-line non-small cell lung cancer (NSCLC) patients. The trial targets patients who have shown resistance to prior checkpoint inhibitor therapies and chemotherapy. The amended clinical supply agreement with Regeneron, initially established in 2021, is set to provide an additional supply of Libtayo® for the expanded trial.
MAIA Biotechnology sponsors the THIO-101 trial and maintains an exclusive worldwide patent license to develop and commercialize THIO. The company is also considering an accelerated approval pathway in the United States based on the trial's outcomes.
The Phase 2 trial of THIO has revealed promising interim results. The trial is evaluating the efficacy of THIO in combination with Regeneron’s immune checkpoint inhibitor cemiplimab for patients who have not responded to two or more standard-of-care therapy regimens. The interim median survival follow-up for these third-line patients was reported at 10.6 months, which compares favorably to the standard-of-care overall survival of 5.8 months. MAIA anticipates releasing full efficacy results from the trial within the current year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.